EZH2 and neoplasm: Indeed, reconstitution of Ezh2, but not its inactive methyltransferase mutant either by F667I mutation, or by deletion of the catalytic SET domain, fully reversed MHC-I expression levels in Usp22-null tumor cells (Supplemental Figure 8, D–F).